Personalised medicine has been targeted as the most important future development in both medicine and drug development. The final product that synergistically combines the two companies' capabilities will be a software platform.
Increasing the bioavailability and targeted delivery of active ingredients - curcumin.
An innovative lipid emulsion that provides in a single lipid all the necessary fatty acids in correct amounts and ratios, specifically tailored to the neonate's needs. By providing a balanced and complete parenteral nutrition for neonates, it will reduce the risks of complications.
Based on anima's protein synthesis monitoring (psm) technology we will develop assays for measuring local protein synthesis in neurons, aiming to characterise the autism spectrum of disorders (asd). Success can lead to a novel tool for studying a range of neuronal disorders.